Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism

Marine Germain, Daniel I. Chasman, Hugoline De Haan, Weihong Tang, Sara Lindström, Lu Chen Weng, Mariza De Andrade, Marieke C.H. De Visser, Kerri L. Wiggins, Pierre Suchon, Noémie Saut, David M. Smadja, Grégoire Le Gal, Astrid Van Hylckama Vlieg, Antonio Di Narzo, Ke Hao, Christopher P. Nelson, Ares Rocanin-Arjo, Lasse Folkersen, Ramin MonajemiLynda M. Rose, Jennifer A. Brody, Eline Slagboom, Dylan Aïssi, France Gagnon, Jean Francois Deleuze, Panos Deloukas, Christophe Tzourio, Jean Francois Dartigues, Claudine Berr, Kent D. Taylor, Mete Civelek, Per Eriksson, Bruce M. Psaty, Jeanine Houwing-Duitermaat, Alison H. Goodall, François Cambien, Peter Kraft, Philippe Amouyel, Nilesh J. Samani, Saonli Basu, Paul M. Ridker, Frits R. Rosendaal, Christopher Kabrhel, Aaron R. Folsom, John Heit, Pieter H. Reitsma, David Alexandre Trégouët, Nicholas L. Smith, Pierre Emmanuel Morange

Research output: Contribution to journalArticlepeer-review

133 Scopus citations


Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a complex thrombotic disorder with environmental and genetic determinants. Although several genetic variants have been found associated with VTE, they explain a minor proportion of VTE risk in cases. We undertook a meta-analysis of genome-wide association studies (GWASs) to identify additional VTE susceptibility genes. Twelve GWASs totaling 7,507 VTE case subjects and 52,632 control subjects formed our discovery stage where 6,751,884 SNPs were tested for association with VTE. Nine loci reached the genome-wide significance level of 5 × 10-8 including six already known to associate with VTE (ABO, F2, F5, F11, FGG, and PROCR) and three unsuspected loci. SNPs mapping to these latter were selected for replication in three independent case-control studies totaling 3,009 VTE-affected individuals and 2,586 control subjects. This strategy led to the identification and replication of two VTE-associated loci, TSPAN15 and SLC44A2, with lead risk alleles associated with odds ratio for disease of 1.31 (p = 1.67 × 10-16) and 1.21 (p = 2.75 × 10-15), respectively. The lead SNP at the TSPAN15 locus is the intronic rs78707713 and the lead SLC44A2 SNP is the non-synonymous rs2288904 previously shown to associate with transfusion-related acute lung injury. We further showed that these two variants did not associate with known hemostatic plasma markers. TSPAN15 and SLC44A2 do not belong to conventional pathways for thrombosis and have not been associated to other cardiovascular diseases nor related quantitative biomarkers. Our findings uncovered unexpected actors of VTE etiology and pave the way for novel mechanistic concepts of VTE pathophysiology.

Original languageEnglish (US)
Pages (from-to)532-542
Number of pages11
JournalAmerican journal of human genetics
Issue number4
StatePublished - Apr 2 2015

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism'. Together they form a unique fingerprint.

Cite this